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VISION IMPAIRMENT AS AN INDEPENDENT
RISK FACTOR OF INSTITUTIONALIZATION 
Brézin A1, Lafuma A2, Fagnani F3, Mesbah M4, Berdeaux G5
1Hopital COCHIN, Paris, France; 2Cemka, Bourg-La-Reine,
France; 3CEMKA, Bourg la Reine, France; 4Université de
Bretagne-Sud,Vannes, France; 5Alcon, Rueil-Malmaison, France
OBJECTIVES: To estimate the risk of being in institu-
tion with vision impairment. METHODS: Two national
surveys were pooled together: 1) 2075 institutions (chil-
dren or adults with handicap, old people and psychiatric
centers) were selected at random from the French Health
Ministry ﬁles in 18 predeﬁned strata. Of the 15,403 
subjects taken at random, 14,603 interviews (94.9%)
documented handicap; and 2) Level of handicap was doc-
umented in a randomized, stratiﬁed sample of 356,208
citizens living in the community. From this sample,
21,760 subjects were further selected at random and
16,945 persons were interviewed. Handicaps (vision,
audition, speaking, brain, visceral, motor and other) and
activity of daily living (ADL) were then collected. The
odds-ratio (OR) of being in institution was estimated
using stepwise logistic regressions with age, geographical
area, handicaps and ADL as co-variables. RESULTS:
Patients in institution were more often female (64.3%
versus 52.4%) and older (68.7 versus 38.0 years old) then
patient living at home. They more often had handicaps
(OR—speaking: 6.56; brain: 6.39; motor: 4.40; visceral:
2.87; audition: 2.37; other: 1.39). They were less often
able to perform their ADL (46.2% versus 97.1%) without
assistance. The OR to be in institution when having vision
handicap was 8.40 without adjustment. This ﬁgure
became 1.53 after adjustment on age, geographical area
and other handicaps and 1.24 after adjustment on age,
geographical area and ADL. CONCLUSION: Vision
handicap is an independent risk factor of institutional-
ization. Preserving vision on long term might reduce or
postpone old subject’s institutionalization by controlling
incapacity and dependency.
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SCORING OF VISUAL FIELD MEASURED
THROUGH HUMPHREY PERIMETRY: PRINCIPAL
COMPONENT VARIMAX ROTATION FOLLOWED
BY CLUSTERING ANALYSIS
Nordmann J1, Mesbah M2, Berdeaux G3
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OBJECTIVES: To issue orthogonal scores from the 52
standardized data collected by a Humphrey visual ﬁeld
(VF) perimetry that maximize between-variance and 
minimize within-variance. METHODS: 437 VF were col-
lected and classiﬁed into 7 clinical groups: irregularities
of VF (IVF), Nasal step (NaS), Arcuate scotoma (AC),
Para-central scotoma (PCS), Blind spot enlargement
(BSE), Diffuse deﬁcit (DD), Advanced deﬁcit (AD).
Number and contents of scores were identiﬁed using a
principal component analysis (Varimax) followed by an
ascending hierarchical clustering analysis. Internal con-
sistency was checked with Cronbach alpha. Scores were
compared across the clinical groups with an Anova.
RESULTS: Patients totaling 54.7% of the patients were
older than 60. Mean defect was -9.21 on average and
PSD was 6.50. Six scores were identiﬁed: 4 peripheral
scores (Nasal Superior NS, Nasal Inferior NI, Temporal
Superior TS, Temporal Inferior TI) and 2 para-central
scores (superior PCSS, inferior PCSI). Cronbach alphas
were always between 0.90 and 0.97. The six scores
decreased simultaneously from IVF, DD to AD. AC had
lower scores in NS, NI and TS. PCS had a lower PCSS.
BSE had lower scores in TS and TI. NaS had lower scores
in NS and NI. CONCLUSION: Six orthogonal scores
were found to be optimal from the Humphrey perimetry
matrix. Internal reliability was good. Ability to discrimi-
nate between clinical subgroups was found. Further
analyses on longitudinal data need to be performed to
conﬁrm our ﬁndings.
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COST AND EFFECTIVENESS OF BRINZOLAMIDE
VERSUS DORZOLAMIDE IN THE TREATMENT
OF GLAUCOMA: AN ANALYSIS CONDUCTED
USING THE UNITED-KINGDOM GENERAL
PRACTITIONER RESEARCH DATABASE
Lafuma A1,Voinet C1, Berdeaux G2
1Cemka, Bourg-La-Reine, France; 2Alcon, Rueil-Malmaison,
France
OBJECTIVE: To compare the cost and effectiveness of
brinzolamide and dorzolamide using data collected in the
United-Kingdom General Practitioner Research Database
METHODS: Files of patients with a diagnosis of ocular
hypertension or glaucoma, or treated with a topical IOP
lowering treatment were extracted. Patients starting treat-
ment with dorzolamide or brinzolamide from August
2000 were selected. A treatment failure was deﬁned as a
regimen change (adding or removing a topical treatment).
Time to treatment failure was compared using a Cox
model. The economic perspective was that of the NHS.
The annual cost of therapy changes by treatment line
(ﬁrst, second, etc.) was calculated for year 2000; visit,
medication and hospitalization costs were included.
RESULTS: Of 49,799 patients selected, 146 were treated
with brinzolamide and 1230 with dorzolamide. No sta-
tistically signiﬁcant differences were found between the 2
groups in terms of patient and disease characteristics.
Patients averaged 72.9 years old and were 56% female.
Prescriptions totaling 21.1% of the prescriptions involved
monotherapy and 14.8% were for ﬁrst line treatment.
After 1 year, 29.8% of the brinzolamide patients experi-
enced a treatment failure compared to 46.0% with 
